Anisah Azhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anisah Azhar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Norhafiza Mohd Arshad
Centre for Research in Biotechnology for Agriculture (CEBAR), Universiti Malaya, Kuala Lumpur, Malaysia
2 shared publications - Swee-Seong Tang
Division of Microbiology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
2 shared publications - Hasniyati Muin
Universiti Malaya Institute of Biological Sciences Federal Territory of Kuala Lumpur Malaysia
1 shared publication - Norhidayah Mohd Taufek
Aqua Nutri Biotechnology Laboratory, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia
1 shared publication - Nur Syazana Aziz
Division of Microbiology, Institute of Biological Sciences (ISB), Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia
1 shared publication - Subha Bhassu
Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, 50603, Malaysia
1 shared publication
Latest Publications
- 20 April 2026
- Published by Springer Nature in Archives of Microbiology
- Vol. 208 (7) , 345
Therapeutic and immunomodulatory effects of phage therapy in red hybrid tilapia challenged with Klebsiella pneumoniae
The increasing prevalence of antibiotic-resistant Klebsiella pneumoniae poses a serious threat to aquaculture sustainability and fish health. This study evaluated the therapeutic efficacy and immunomodulatory effects of Klebsiella pneumoniae Phage 5 (KPP5) in red hybrid tilapia experimentally challenged with K. pneumoniae strain 001 (KP001). In vitro characterisation demonstrated that the phage exhibited strong lytic activity, rapid replication, and a high burst size against the target bacterium. An in vivo challenge model was established to assess disease progression, survival, bacterial clearance, phage persistence, and host immune responses following intraperitoneal administration. Phage-treated fish exhibited a 41.67% relative survival, a complete hepatic bacterial clearance, and a sustained phage persistence. Phage titres persisted longer in infected fish, indicating active replication in the presence of the bacterial host. Immunological analyses revealed that phage therapy moderated excessive inflammatory responses while enhancing protective immunity, as evidenced by stabilised protein levels, regulated complement activity, partial restoration of lysozyme activity, and significantly elevated immunoglobulin M (IgM) concentrations in both serum and mucus. These findings demonstrate that KPP5 provides dual benefits through effective bacterial control and modulation of innate and adaptive immune responses. Overall, this study supports the potential of bacteriophage therapy as a safe and promising alternative strategy for managing antibiotic-resistant bacterial infections in aquaculture. This study was registered with the Institutional Animal Care and Use Committee (IACUC) of Universiti Malaya (Ref: G8/10032025/07012025-02/R).
- 20 April 2026
- Published by Springer Nature in Archives of Microbiology
- Vol. 208 (7) , 345
Therapeutic and immunomodulatory effects of phage therapy in red hybrid tilapia challenged with Klebsiella pneumoniae
The increasing prevalence of antibiotic-resistant Klebsiella pneumoniae poses a serious threat to aquaculture sustainability and fish health. This study evaluated the therapeutic efficacy and immunomodulatory effects of Klebsiella pneumoniae Phage 5 (KPP5) in red hybrid tilapia experimentally challenged with K. pneumoniae strain 001 (KP001). In vitro characterisation demonstrated that the phage exhibited strong lytic activity, rapid replication, and a high burst size against the target bacterium. An in vivo challenge model was established to assess disease progression, survival, bacterial clearance, phage persistence, and host immune responses following intraperitoneal administration. Phage-treated fish exhibited a 41.67% relative survival, a complete hepatic bacterial clearance, and a sustained phage persistence. Phage titres persisted longer in infected fish, indicating active replication in the presence of the bacterial host. Immunological analyses revealed that phage therapy moderated excessive inflammatory responses while enhancing protective immunity, as evidenced by stabilised protein levels, regulated complement activity, partial restoration of lysozyme activity, and significantly elevated immunoglobulin M (IgM) concentrations in both serum and mucus. These findings demonstrate that KPP5 provides dual benefits through effective bacterial control and modulation of innate and adaptive immune responses. Overall, this study supports the potential of bacteriophage therapy as a safe and promising alternative strategy for managing antibiotic-resistant bacterial infections in aquaculture. This study was registered with the Institutional Animal Care and Use Committee (IACUC) of Universiti Malaya (Ref: G8/10032025/07012025-02/R).
- Open Access
- 24 February 2026
- Published by Wiley in Aquaculture, Fish and Fisheries
- Vol. 6 (1)
Expanding Horizons in Phage Therapy: Addressing Antibiotic Resistance in Aquaculture
Aquaculture has emerged as a cornerstone of global food security, yet its rapid intensification has precipitated widespread bacterial disease outbreaks and escalating antimicrobial resistance (AMR). This review critically examines the limitations of conventional antibiotic use in aquaculture, highlighting regulatory inconsistencies, environmental risks and the proliferation of resistant pathogens. In response, bacteriophage (phage) therapy is gaining traction as a targeted, sustainable alternative. The article synthesizes recent advances in phage isolation, characterization and delivery methods, emphasizing their specificity, immunomodulatory effects and ability to penetrate biofilms without disrupting host microbiota. Notably, phages demonstrate efficacy against key aquaculture pathogens such as Aeromonas , Vibrio and Streptococcus species across diverse aquatic hosts. The review also explores phage–host dynamics, optimal dosing strategies and the role of encapsulation technologies in enhancing stability and gastrointestinal survivability. Despite promising therapeutic outcomes, several challenges persist, including bacterial resistance via receptor mutation, quorum‐sensing modulation and environmental stressors. Regulatory and commercial barriers further hinder widespread adoption, with gaps in standardized protocols, safety assessments and economic feasibility. Genetically modified phages offer enhanced precision but raise ethical and ecological concerns. To bridge these divides, the article advocates for harmonized regulatory frameworks, region‐specific trials and the establishment of validated phage repositories. Phage therapy marks a transformative advancement in aquaculture health management, offering a targeted, eco‐conscious and economically sustainable alternative to antibiotics. Ultimately, its successful integration hinges on robust scientific validation, ethically sound oversight and cohesive collaboration across disciplines.
- 24 February 2026
- Published by Wiley in Aquaculture, Fish and Fisheries
- Vol. 6 (1)
Open AccessExpanding Horizons in Phage Therapy: Addressing Antibiotic Resistance in Aquaculture
Aquaculture has emerged as a cornerstone of global food security, yet its rapid intensification has precipitated widespread bacterial disease outbreaks and escalating antimicrobial resistance (AMR). This review critically examines the limitations of conventional antibiotic use in aquaculture, highlighting regulatory inconsistencies, environmental risks and the proliferation of resistant pathogens. In response, bacteriophage (phage) therapy is gaining traction as a targeted, sustainable alternative. The article synthesizes recent advances in phage isolation, characterization and delivery methods, emphasizing their specificity, immunomodulatory effects and ability to penetrate biofilms without disrupting host microbiota. Notably, phages demonstrate efficacy against key aquaculture pathogens such as Aeromonas , Vibrio and Streptococcus species across diverse aquatic hosts. The review also explores phage–host dynamics, optimal dosing strategies and the role of encapsulation technologies in enhancing stability and gastrointestinal survivability. Despite promising therapeutic outcomes, several challenges persist, including bacterial resistance via receptor mutation, quorum‐sensing modulation and environmental stressors. Regulatory and commercial barriers further hinder widespread adoption, with gaps in standardized protocols, safety assessments and economic feasibility. Genetically modified phages offer enhanced precision but raise ethical and ecological concerns. To bridge these divides, the article advocates for harmonized regulatory frameworks, region‐specific trials and the establishment of validated phage repositories. Phage therapy marks a transformative advancement in aquaculture health management, offering a targeted, eco‐conscious and economically sustainable alternative to antibiotics. Ultimately, its successful integration hinges on robust scientific validation, ethically sound oversight and cohesive collaboration across disciplines.